EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan

Satoshi Miyamoto iD, Akihiro Tsukaguchi, Hanako Kuhara, Taiichiro Otsuki, Takayuki Shiroyama, Motohiro Tamiya, Akihiro Tamiya, Kazumi Nishino, Yoshito Takeda, Takashi Kijima, Meinoshin Okumura, Atsushi Kumanogoh und 1 weitere

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70047 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Satoshi Miyamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Thymus Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenvatinib is recommended for the treatment of advanced and recurrent thymic carcinomas. However, there is a paucity of data on lenvatinib's use in real‐world clinical practice. The aim of this study was to evaluate the efficacy and safety of lenvatinib in patients with thymic carcinoma.

Methods

This multicenter retrospective cohort study assessed the efficacy and tolerability of lenvatinib in the treatment of patients with advanced or recurrent thymic carcinoma between March 2021 and March 2024.

Results

Twenty‐seven patients from six institutions in Japan were enrolled in this study. The median progression‐free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were 9.0 months (95% confidence interval [CI] 4.8–14.5), 33% (95% CI 16.5%–54%), and 85% (95% CI 66.3%–95.8%), respectively. Although the number of patients was small, the median PFS of the first‐, second‐, and third‐ or later‐line treatment groups was 21.3 months ( n = 5), 9.0 months ( n = 13), and 5.8 months ( n = 9) ( p = 0.171), respectively. Dose reduction was required in all patients, with 17 (63%) presenting grade ≥ 3 adverse events, including hypertension in seven patients and proteinuria in six. No grade ≥ 4 adverse events were observed.

Conclusion

The real‐world efficacy and safety of lenvatinib are consistent with those reported in previous clinical trials of second‐line lenvatinib. Furthermore, despite the relatively small sample size, our findings suggest that lenvatinib may be effective for the treatment of thymic carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesThymus NeoplasmsNeoplasm Recurrence, LocalThymomaAntineoplastic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedJapanAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

lenvatinibretrospective studythymic carcinomavascular endothelial growth factor

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.
  • Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Internal Medicine, NHO Kinki-Chuo Chest Medical Center, Osaka, Japan.
  • Department of Internal Medicine, Saito Yukoukai Hospital, Ibaraki, Osaka, Japan.
  • Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.

ORCID-Profile: Satoshi Miyamoto

Zitieren

APA

Miyamoto, S., Tsukaguchi, A., Kuhara, H., Otsuki, T., Shiroyama, T., Tamiya, M., Tamiya, A., Nishino, K., Takeda, Y., Kijima, T., Okumura, M., Kumanogoh, A., & Mori, M. (2025). Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70047

Vancouver

Miyamoto S, Tsukaguchi A, Kuhara H, Otsuki T, Shiroyama T, Tamiya M, et al. Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70047

BibTeX
@article{Miyamoto2025,
  author = {Miyamoto, Satoshi and Tsukaguchi, Akihiro and Kuhara, Hanako and Otsuki, Taiichiro and Shiroyama, Takayuki and Tamiya, Motohiro and Tamiya, Akihiro and Nishino, Kazumi and Takeda, Yoshito and Kijima, Takashi and Okumura, Meinoshin and Kumanogoh, Atsushi and Mori, Masahide},
  title = {Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70047}
}
Kostenlos starten →